Across the recent three months, 18 analysts have shared their insights on Biogen BIIB, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 11 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 3 | 3 | 5 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident in the current average compared to the previous average price target of $257.94.
Interpreting Analyst Ratings: A Closer Look
The standing of Biogen among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Geoff Meacham | Citigroup | Lowers | Neutral | $160.00 | $190.00 |
| Mohit Bansal | Wells Fargo | Lowers | Equal-Weight | $165.00 | $190.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Buy | $220.00 | $302.00 |
| Christopher Raymond | Piper Sandler | Lowers | Neutral | $138.00 | $315.00 |
| Evan Seigerman | BMO Capital | Lowers | Market Perform | $164.00 | $230.00 |
| Tim Anderson | B of A Securities | Announces | Neutral | $178.00 | - |
| Michael Yee | Jefferies | Lowers | Hold | $180.00 | $250.00 |
| Salim Syed | Mizuho | Lowers | Outperform | $207.00 | $251.00 |
| Ami Fadia | Needham | Maintains | Hold | $270.00 | $270.00 |
| Brian Skorney | Baird | Raises | Outperform | $300.00 | $294.00 |
| Geoff Meacham | Citigroup | Announces | Neutral | $190.00 | - |
| Chris Schott | JP Morgan | Lowers | Neutral | $210.00 | $220.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $255.00 | $270.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $180.00 | $190.00 |
| Phil Nadeau | TD Cowen | Lowers | Buy | $275.00 | $300.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | $300.00 |
| Ami Fadia | Needham | Maintains | Buy | $270.00 | $270.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Equal-Weight | $204.00 | $285.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Biogen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Biogen's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Biogen analyst ratings.
Delving into Biogen's Background
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Biogen's Economic Impact: An Analysis
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.76%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Biogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching 1.41%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
